Brokerages expect Catalyst Biosciences Inc (NASDAQ:CBIO) to report earnings per share of ($0.59) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences reported earnings per share of ($0.96) during the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The company is expected to issue its next earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Catalyst Biosciences will report full year earnings of ($2.27) per share for the current fiscal year. For the next financial year, analysts forecast that the business will post earnings of ($2.86) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Friday, November 2nd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.05). Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 22.67%.
A number of hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC increased its holdings in Catalyst Biosciences by 303.3% during the third quarter. AQR Capital Management LLC now owns 93,769 shares of the biopharmaceutical company’s stock valued at $1,011,000 after buying an additional 70,519 shares during the last quarter. Nexthera Capital LP increased its holdings in Catalyst Biosciences by 13.4% during the third quarter. Nexthera Capital LP now owns 892,579 shares of the biopharmaceutical company’s stock valued at $9,622,000 after buying an additional 105,714 shares during the last quarter. Sio Capital Management LLC increased its holdings in Catalyst Biosciences by 16.9% during the third quarter. Sio Capital Management LLC now owns 550,977 shares of the biopharmaceutical company’s stock valued at $5,940,000 after buying an additional 79,529 shares during the last quarter. Prosight Management LP purchased a new stake in Catalyst Biosciences during the third quarter valued at approximately $2,550,000. Finally, JBF Capital Inc. purchased a new stake in Catalyst Biosciences during the third quarter valued at approximately $323,000. 67.14% of the stock is owned by institutional investors and hedge funds.
Shares of CBIO traded up $0.13 during mid-day trading on Monday, hitting $10.68. 154,957 shares of the company traded hands, compared to its average volume of 179,426. Catalyst Biosciences has a 1 year low of $6.26 and a 1 year high of $37.00. The stock has a market capitalization of $126.00 million, a price-to-earnings ratio of -1.43 and a beta of 2.36.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.